Open AccessImpact of proactive low-molecular weight heparin therapy on outcomes in COVID-1
Author(s) -
Selçuk Görmez,
Hilal Kurtoğlu Gümüşel,
Erkan Ekicibaşi,
Aleks Değirmencioğlu,
Atmika Paudel,
Gökçe Akan,
Fatmahan Atalar,
Refik Erdim,
Emre Eroğlu,
Selçuk Dağdelen,
Nevin Sarıgüzel,
Ceyda Kirisoglu,
Burak Pamukçu
Publication year - 2021
Publication title -
bratislavské lekárske listy/bratislava medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 32
eISSN - 1336-0345
pISSN - 0006-9248
DOI - 10.4149/bll_2021_093
Subject(s) - covid-19 , heparin , medicine , low molecular weight heparin , intensive care medicine , virology , disease , outbreak , infectious disease (medical specialty)
Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission.